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Abstract
HIV/AIDS has had a profound impact on children around the world since the start of the epidemic. 
There are currently 3.4 million children under the age of 15 years living with HIV globally, and 
more than 450,000 children currently receiving lifesaving antiretroviral treatment. This article 
describes efforts supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) to 
expand access to treatment for children living with HIV in high-burden countries. The article also 
highlights a series of case studies that illustrate the impact that the PEPFAR initiative has had on 
the pediatric HIV epidemic. Through its support of host governments and partner organizations, 
the PEPFAR initiative has expanded HIV testing and treatment for pregnant women to reduce 
vertical transmission of HIV, increased access to early infant diagnosis for HIV-exposed infants, 
improved training and resources for clinicians who provide pediatric care and antiretroviral 
treatment, and, through public–private partnerships with pharmaceutical manufacturers, helped 
increase the number of medications available for the treatment of HIV-infected children in 
resource-limited settings.
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In 2000 at the 13th International AIDS Conference in Durban, South Africa, Nkosi Johnson, 
a 12-year-old boy living with HIV infection, issued a challenge to the global community. 
“Care for us,” he said, “and accept us—we are all human beings. We are normal. We have 
hands. We have feet. We can walk, we can talk, we have needs just like everyone else—don’t 
be afraid of us—we are all the same!”1 He spoke for the millions of people in the world who 
were succumbing to the ravages of the AIDS epidemic, and his small, frail body and strained 
voice provided a vivid image of pediatric HIV disease. At the time, HIV had emerged as a 
major threat to child health worldwide and particularly in sub-Saharan Africa where an 
estimated 2 million children were living with HIV infection.2 In 2000, more than 1600 
children were newly acquiring HIV infection each day, primarily through mother-to-child 
perinatal transmission, and 3.8 million pediatric deaths had already been attributed to HIV/
AIDS.2
In the initial 20 years after the first cases of AIDS were described in children,3 clinicians and 
scientists became well acquainted with manifestations of pediatric HIV infection and the 
particular challenges of providing effective care. In the absence of antiretroviral treatment 
(ART), HIV infection is a rapidly progressive and fatal disease in infants: 50% of HIV-
infected babies in Africa died before reaching their second birthday.4 Many of those who 
survived the first years of life suffered a broad range of multiorgan manifestations including 
high rates of encephalopathy, developmental delays, short stature, failure to thrive, 
pulmonary compromise, frequent infections, and other debilitating complications for which 
treatments were rarely available.5-9 Children with HIV most often came from families where 
HIV both infected and affected multiple family members, devastating the core of family life 
and leaving many orphaned and emotionally fragile children.10 In particular, pregnant 
women with advanced HIV disease were at high risk for death and for perinatal transmission 
of rapidly progressive disease to their infants.11-13 And compared with children born to HIV-
uninfected women, even those HIV-exposed infants who escaped perinatal HIV infection 
were at substantially higher risk for common childhood illnesses and mortality.14-16
Furthermore, characteristics of pediatric HIV infection posed and continue to pose 
challenges to the establishment of effective HIV care and treatment services. Although most 
children acquire HIV infection through perinatal transmission, not all infants born to HIV-
positive mothers become infected.17 Distinguishing the infected from the uninfected infant 
requires sophisticated laboratory tests [such as HIV DNA polymerase chain reaction (PCR)], 
which exceeded the laboratory capacity of most resource-constrained settings.18 Without 
early diagnosis and initiation of ART, HIV-infected infants remain at high risk for severe 
disease manifestations and early death.4,19 Children with HIV are also particularly 
vulnerable to other health threats such as malaria, tuberculosis, and malnutrition, which both 
weaken the child’s natural responses to fight HIV and complicate treatment efforts.20-24 
ART options for children, particularly young children, are also complicated by limited 
availability of palatable, suitable, child-friendly formulations and drug–drug interactions 
with other commonly used medications such as antimyco-bacterial agents.25-27 In countries 
with the highest concentration of children living with HIV, health systems accustomed to 
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providing acute episodic health care services are ill equipped to offer the chronic, continuous 
multidimensional care across the developmental spectrum from infancy through childhood 
and adolescence that is necessary to effectively treat pediatric HIV disease. Finally, similar 
to adults with HIV infection, children with HIV and their families struggle to maintain strict 
adherence to complex medication regimens and to cope with and manage the impact of 
stigma and discrimination.28
Against this backdrop, the global community mobilized to address the HIV pandemic and 
expand access to HIV services for children and families in sub-Saharan Africa and other 
high-burden, low-resource settings. We describe the efforts of the President’s Emergency 
Program for AIDS Relief (PEPFAR) to expand HIV services to infants, children, and 
adolescents living with HIV infection.
 PEPFAR RESPONSE
PEPFAR was initiated by the US Government (USG) in 2003 to help combat the global 
HIV/AIDS epidemic. The program was founded to help countries scale-up HIV care and 
treatment programs and to undertake expanded efforts to prevent new HIV infections. In 
2011, PEPFAR directly supported HIV testing and counseling for more than 40 million 
people and provided ART for more than 3.9 million men, women, and children.29 These 
efforts have been accomplished through bilateral support to countries, and through the work 
of implementing government agencies and PEPFAR-funded international and local 
nongovernmental partner organizations, which have provided technical support to host 
governments, implemented service programs, and assisted in the development of new 
international and national guidelines.
To rapidly scale-up HIV care and treatment for children, PEPFAR initially funded and 
partnered with ministries of health (MOHs) and partner organizations30,31 to provide a 
family-based approach to pediatric HIV service delivery in its 15 focus countries. Table 1 
describes the burden of pediatric HIV in these 15 focus countries32-34 and shows that, in 
2010, PEPFAR support was responsible for provision of ART to 83.8% of the estimated 
number of children receiving treatment in these countries.
In efforts to promote pediatric HIV training, routine HIV testing of children, pediatric HIV 
care and treatment, and laboratory capacity building, PEPFAR leveraged the resources of 
adult HIV care and treatment programs. PEPFAR promoted the integration of pediatric HIV 
services into maternal and child health settings to strengthen pediatric HIV prevention, early 
infant diagnosis, and care for HIV-exposed and HIV-infected infants. Working through its 
governmental and nongovernmental partners, PEPFAR introduced pilot pediatric HIV 
programs in Guyana and 9 countries in sub-Saharan Africa in 200435; by 2006, all 15 focus 
countries had established programs to support pediatric HIV care and ART.
The earliest sites providing pediatric services were located in large urban hospitals offering 
specialized pediatric clinics or “pediatric days” providing services only to children. PEPFAR 
supported partner organizations as they established pediatric HIV centers of excellence in 
countries such as Zambia, Rwanda, and Uganda. These large urban health care facilities 
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served as regional referral sites for HIV-infected children and as training centers for 
clinicians and allied health workers.
PEPFAR also directly contributed to the expansion of pediatric HIV services by supporting 
the development of clinical and psychosocial training curricula and national and 
international pediatric HIV guidelines and policies (see Case Study I: Pediatric Provider-
Initiated Testing and Counseling in Zambia). By funding public health program evaluations, 
PEPFAR has helped build an evidence base to inform best practices and guideline 
development.36-39 After recognizing the need for simple job aids for health care workers in 
resource-limited settings providing pediatric care, PEPFAR helped expand the use of the 
first weight-band dosing charts for pediatric ART.40,41 USG staff also designed a series of 
early infant diagnosis (EID) manuals and an instructional video to strengthen the capacity of 
nurses and clinicians, national HIV program managers, and laboratory staff to implement 
high-quality EID programs.42 PEPFAR’s international partners were also instrumental in 
developing pediatric HIV guidance documents, toolkits, and educational materials, such as 
the Handbook on Paediatric AIDS in Africa developed by the African Network for the Care 
of Children Affected by AIDS (ANECCA; see Case Study II: Regional Capacity).
By expanding pediatric HIV training, supporting simplification of pediatric ART regimens, 
and advocating for task shifting from pediatricians to general physicians, nurses, and clinical 
officers, PEPFAR promoted decentralization of EID and pediatric HIV care and treatment to 
primary health facilities. Decentralization of pediatric HIV services has resulted in a 
dramatic increase in the number of children receiving care and starting treatment43 (see Case 
Study III: National EID Program in Mozambique). Between 2006 and 2011, there was more 
than a 6-fold increase in the number of children receiving ART in the 15 PEPFAR focus 
countries, from 44,800 children in 2006 to 289,600 in 2011 (Fig. 1).
As part of PEPFAR activities, USG agencies, including the Centers for Disease Control and 
Prevention and the US Agency for International Development, promoted the expansion of 
high-quality pediatric care and treatment programs through a variety of activities. In 2005, a 
PEPFAR technical working group devoted to prevention of mother-to-child transmission 
(PMTCT) and pediatric HIV care and treatment was created. Among other activities, this 
group was charged with developing technical guidance documents and identifying areas of 
emphasis for pediatric HIV programs. These documents have guided country-level technical 
working groups and program mangers as they developed national guidelines, program 
priorities and implementation plans, and educational curricula. Key areas have included the 
following: scaling up cotrimoxazole prophylaxis; developing guidance for a preventive care 
package for HIV-exposed children44; adapting World Health Organization (WHO) treatment 
guidelines to the country level; early identification of HIV infection in infants; integrating 
HIV and maternal, neonatal, and child health45; improving retention in care; and 
strengthening laboratory and supply chain systems to support drugs, laboratory reagents, and 
blood drawing equipment for children.
Several management tools are used by PEPFAR to advance pediatric care and treatment. To 
promote of ART for young infants, PEPFAR requires reporting of treatment results 
disaggregated by age groups, including the group of <1 year of age. In generalized 
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epidemics, PEPFAR targets call for 65% coverage of HIV-exposed children with EID, and 
treatment of pediatric populations proportional to their representation in the overall 
population of HIV-infected people in the country.46 Finally, PEPFAR developed budget 
codes that cover pediatric care and treatment to better track resources devoted to supporting 
HIV-infected children.
PEPFAR launched several innovative initiatives to accelerate the scale-up of pediatric care 
and treatment. As part of the US Food and Drug Administration’s expedited review process 
for antiretroviral (ARV) medications for use in PEPFAR, a number of generic pediatric ARV 
formulations, including zidovudine, stavudine, lamivudine, didano-sine, nevirapine, and 
abacavir, were “tentatively approved,” allowing the use of PEPFAR funds for purchase.27,47 
PEPFAR also established a public–private partnership to bring together innovator and 
generic pharmaceutical companies, civil society organizations, and USG agencies to 
promote scientific and technical discussions on pediatric HIV treatment, formulations, and 
access.48 The partnership has helped expedite drug registration, expand the number of 
pediatric ARV formulations, improve forecasting and supply of ARV drugs, advance EID, 
and coordinate provider education and training. Since 2005, 9 fixed-dose combination 
pediatric ARV formulations have been approved by the Food and Drug Administration 
and/or prequalified by the WHO, leading to expanded and simplified treatment options for 
children.27
 CASE STUDY I: PEDIATRIC PROVIDER-INITIATED TESTING AND 
COUNSELING IN ZAMBIA
A critical step to the successful scale-up of effective HIV care and treatment has been the 
early identification of HIV-infected children.4,49-52 In 2005 with PEPFAR funding, the 
University Teaching Hospital of Zambia (UTH) Pediatric HIV/AIDS Center of Excellence 
(COE) partnered with Columbia University’s ICAP to provide comprehensive HIV care and 
treatment for children and to document and disseminate evidence of effective program 
models. A key area of focus for the COE was in developing strategies to increase the number 
of children engaged in care. An innovative provider-initiated testing and counseling (PITC) 
program that offered routine HIV testing and counseling to all children admitted to the 
hospital and to their parents/caregivers and siblings was piloted at UTH starting in 2006.
In the first 18 months of the PITC program, 13,239 (85%) parents/caregivers of children 
admitted to UTH with unknown HIV status received counseling, and over 11,571 (87%) 
children were tested. Testing rates increased over time from 76% in the first quarter of the 
project to 88% in year 2. Of the children tested, 29% were found to be seropositive.53
The evaluation of the pilot demonstrated that PITC for hospitalized children in high–HIV 
prevalence settings is a highly effective strategy to identify large numbers of HIV-infected 
children who could then be linked to care and treatment services. Based on these findings, 
the MOH in collaboration with COE staff developed national guidelines to expand the use of 
PITC in pediatric care settings. Using the experience gained during the pilot program, UTH 
developed a pediatric PITC training curriculum and program for health workers in 
Zambia.54 Hundreds of health care workers have rotated through the COE to participate in 
Abrams et al. Page 5













this didactic and experiential training course. The PITC guidelines and training materials 
have also been adapted for use in multiple African countries.
 CASE STUDY II: REGIONAL CAPACITY
Responding to the escalating numbers of children with HIV infection and the limited 
experience with pediatric HIV programming in sub-Saharan Africa, a small group of 
experienced clinicians formed ANECCA in 2001.55 The organization was established to 
advocate for increased access to quality pediatric HIV prevention, care, and treatment 
services; develop pediatric HIV technical resource materials; build capacity of health 
workers to provide high-quality care; and produce scientific evidence for effective pediatric 
HIV programming in Africa.
With support from PEPFAR and other local and international donors, ANECCA developed a 
variety of resources to support the scale-up of pediatric HIV care and ART. The Handbook 
on Paediatric AIDS in Africa is an easily accessible and practical resource developed by 
African experts with substantial experience caring for children.56 More than 15,000 copies 
have been distributed in over 35 countries, and it is a well-used and valuable tool for 
clinicians throughout the African continent. ANECCA also developed the Comprehensive 
Paediatric HIV/AIDS Care Training Curriculum, a training package for health workers that 
has been adapted and implemented as the national curriculum in over 12 African 
countries.57 ANECCA’s Clinical Mentorship Program and the Clinical Mentorship Toolkit 
for Paediatric HIV Care in Africa have equipped more than 2000 HIV clinicians to mentor 
others providing health care to children with HIV infection. ANECCA has greatly 
contributed to building pediatric HIV expertise in Africa, and this will continue to serve as a 
model for the next generations of health care workers.
More than 1000 African practitioners from more than 20 African countries are currently 
members of ANECCA, and the organization continues to identify critical emerging issues in 
the field and advocate for scientifically-informed mechanisms to scale-up high-quality care 
for children. Regional consultations bring together a broad range of stakeholders invested in 
care of children and provide an opportunity for exchange and innovation. For example, the 
proposal to include HIV exposure status on the child health card originated during an 
ANECCA forum. This proposal has already resulted in policy change and has the potential 
to improve child health outcomes throughout the continent.
 CASE STUDY III: NATIONAL EID PROGRAM IN MOZAMBIQUE
During the early years of the scale-up of HIV services in Mozambique, most pediatric 
patients starting ART were older children with established HIV infection. The number of 
infants and young children on treatment was disproportionately low and particularly 
problematic given the risk of early disease progression and death in the first year of life.4 
Failure to identify and treat more young children was attributed to limited laboratory 
capacity for specialized virological testing required for HIV diagnosis among infants.
In 2005, with support from PEPFAR partners, EID testing with HIV DNA PCR was 
established at the MOH National Institute of Health laboratory. An initial pilot conducted at 
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the Pediatric Day Hospital in Maputo validated the use of dried blood spots (DBS) to 
conduct PCR testing and informed the EID national roll-out over the subsequent 2 years. 
DBS facilitated both specimen collection (not necessitating venipuncture) and transport 
(using filter paper rather than specimen tubes).
Intensive nationwide training of nurses on DBS collection and medical officers and doctors 
on pediatric HIV treatment was conducted. Three additional laboratories were equipped and 
laboratory technicians trained to perform PCR testing and strategically placed to ensure 
access to EID throughout the country. By 2007, 70 health facilities collected 5893 DBS 
samples. In 2011, DBS samples were collected at 270 facilities and 35,970 samples were 
tested.
A DBS sample referral network using Internet communication and general packet radio 
service technology, a mobile data service, was established to ensure timely provision of EID 
results to clinic facilities. Implementation of the system has resulted in measurable decreases 
in the number of lost results and the time from specimen collection to return of results.
By the end of 2011, 23,053 of the estimated 130,000 HIV-infected children living in 
Mozambique had received ART. Over the past 3 years, the proportion of infants on ART 
rapidly increased because of the EID scale-up and improved follow-up of HIV-exposed 
infants. As demonstrated in Figure 2, the proportion of HIV-infected infants initiating ART 
in 142 clinics supported by PEPFAR through the Elizabeth Glaser Pediatric AIDS 
Foundation in 4 provinces in Mozambique increased from 39% to 72% (Fig. 2). This 
noteworthy change can be attributed to improved capacity to identify, diagnose, and treat 
infants and young children in Mozambique.
 CASE STUDY IV: YOUTH-FRIENDLY SERVICES IN BOTSWANA
With improvements in pediatric ART and scale-up of treatment programs, children with HIV 
are living into adolescence and adulthood. It is estimated that over 2 million youth aged 10–
19 years worldwide are living with HIV as a result of mother-to-child transmission and 
behaviorally acquired infection.32 Providing care for adolescents living with HIV has unique 
challenges with regard to testing and disclosure, adherence to treatment, and retention in 
care.58-60 In Botswana, where 2.4% of men and 5% of women aged 15–19 years are living 
with HIV, over 13,000 adolescents aged 10–19 years are estimated to be HIV infected, there 
is an urgent need for targeting services to this population.61 The Botswana MOH and 
international and local organizations have been working to provide a multifaceted response 
to this need.
In early 2010, the Botswana MOH established a technical working group dedicated 
specifically to the needs of adolescents living with HIV. This group is currently developing 
youth-focused treatment guidelines and an “adolescent clinical care package,” which when 
released later this year will recommend minimum adolescent-focused services for all tiers of 
the national health care system.
Similar to many programs throughout sub-Saharan Africa, at the Baylor-Botswana 
Children’s Clinical COE, Gaborone’s largest pediatric HIV referral center, the number of 
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youth in HIV care has increased dramatically from 23 adolescents in 2003 to over 800 in 
2010. A focus of the COE has been to develop tools and programs to support the transition 
of adolescents into adult care, including use of an algorithm to identify when patients are 
ready to transition, and peer programs, including “Young Adult Club,” which support youth 
through the transition process.62
Finally, to improve adherence to treatment and encourage retention in care for adolescents, 
the Kgakololo Project uses instant messaging technology to deliver adherence messages. 
The program leverages existing cell phone coverage and engages local youth in information 
technology skill building. The success of the effort, led by PING (Positive Innovation for the 
Next Generation), has resulted in plans to expand the project to several southern African 
countries.63
 ACHIEVEMENTS, CHALLENGES, AND NEXT STEPS
Efforts to prevent mother-to-child transmission have expanded over the past decade and are 
now escalating in response to the global challenge to meet ambitious targets toward 
elimination of new perinatal infections.64 It is estimated that since 1995, more than 350,000 
pediatric HIV infections have been averted with the provision of ARV medications for 
PMTCT. Although the number of new pediatric infections annually remains unacceptably 
high, at 390,000 in 2010, this number is 30% lower than the 560,000 new pediatric 
infections reported in 2002 and in 2003.32 By the end of 2010, an estimated 3.4 million 
children <15 years of age were living with HIV infection, primarily in sub-Saharan Africa. 
More than 450,000 children were receiving ART by the end of 2010, a 29% increase from 
2009.32 The 250,000 pediatric deaths attributed to HIV in 2010 represents a 20% decline 
from 2005, suggesting a measurable benefit of efforts to identify, engage, and treat children 
with HIV infection.32
Despite these noteworthy successes, millions of children are still in need of HIV care and 
treatment. Coverage estimates for children remain low when compared with adults: in 2010, 
51% of adults in need of ART were receiving treatment versus only 23% of children. 
Currently 1–1.5 million children in need of ART have not yet initiated treatment, and each 
day as many as 1000 children acquire HIV.32 Furthermore, major challenges threaten 
expansion of services and the stability of current successful programs. Incomplete PMTCT 
and EID coverage, low HIV testing rates during childhood and adolescence, poor rates of 
linkages to and retention within treatment programs, and shortages of skilled health workers 
competent to treat children represent a subset of the many issues that will need to be 
addressed to expand HIV services for pediatric populations.65-67 As the international 
community shifts focus and funding to reach ambitious global goals to prevent new pediatric 
infections, it will be critical to continue to address the care and treatment needs of children 
and adolescents living with HIV infection.
Many innovations have successfully been tested within the PEPFAR program (as described 
in more detail in the articles in this journal), and PEPFAR’s continued support of pediatric 
HIV care and treatment programs will be vital for continued success. In particular, continued 
efforts to train nonphysician health workers to provide pediatric care will be critical as will 
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efforts to integrate pediatric HIV care with other community-based or clinic-based 
services.68–70 Furthermore, because pediatric ARV medications contribute only a small 
proportion of the global ARV market, the supply chain is often threatened with delayed 
production, stock outs, and potential discontinuation. It will be critical to rationalize and 
consolidate national pediatric HIV formularies to medications on the WHO essential 
medicines list to ensure a continued supply of pediatric medications.27,71,72 Continued work 
to strengthen public–private partnerships with pharmaceutical companies to support 
development and production of existing and promising new accessibly priced pediatric drugs 
and formulations is needed.
We can also expect that with the expansion of treatment and maturation of existing 
programs, more children will survive into adolescence and adulthood, requiring a 
comprehensive array of services needed to address complex biomedical (treatment failure, 
inadequate adherence, ART-related complications, retention) and psychosocial (disclosure, 
sexuality and contraception, peer relations) issues associated with this disease. The growing 
number of youth living with HIV will also need targeted support as they transition into adult 
HIV care and treatment services (see Case Study IV: Youth-Friendly Services in Botswana).
PEPFAR remains a driving force to expand lifesaving services for HIV-infected children. 
Through its partnerships with MOHs, the international community and implementing 
partners, PEPFAR can continue to provide the needed momentum to expand pediatric HIV 
services. In closing words at the 13th International AIDS Conference, Nelson Mandela 
echoed Nkosi Johnson’s call to the global community. He spoke of the importance of the 
conference as “… a gathering of human beings concerned about turning around one of the 
greatest threats humankind has faced, and certainly the greatest after the end of the great 
wars of the previous century.” He articulated what would become to represent the PEPFAR 
and global response to the epidemic. He said “… Others will not save us if we do not 
primarily commit ourselves. Let us, however, not underestimate the resources required to 
conduct this battle. Partnership with the international community is vital. A constant theme 
in all our messages has been that in this inter-dependent and globalized world, we have 
indeed again become the keepers of our brother and sister. That cannot be more graphically 
the case than in the common fight against HIV/AIDS.”1
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Provision of ART for children aged 0–14 years in PEPFAR focus countries, 2006–2011 
(source: Office of the Global AIDS Coordinator).
*Annual Reports to Congress on the President’s Emergency Plan for AIDS Relief 
(PERFAR). Available online at http://www.pepfar.gov/progress/index.htm.
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Rapid increase in the proportion of HIV-infected infants receiving ART as a result of the 
expansion of EID at 142 facilities in Maputo, Gaza, Nampula, and Cabo Delgado provinces, 
Mozambique, 2008–2011 (courtesy of Elizabeth Glaser Pediatric AIDS Foundation, 
Mozambique).
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TABLE 1
Estimated Number of Children Aged 0–14 Years Living With HIV in PEPFAR Focus Countries and Estimated 
Number of Children Receiving ART From All Sources and From PEPFAR
PEPFAR Focus Country No. Children Living With 
HIV, 2009*




No. Children Receiving 
ART Through PEPFAR 
Support, 2010‡
Botswana 16,000 11,000 10,048 2300
Côte d’Ivoire 52,000§ 37,000 4550 3700
Ethiopia 92,000 Not available 14,056 12,300
Guyana Not available Not available 177 187
Haiti 12,000 8200 1558 1400
Kenya 180,000 170,000 36,096 45,100
Mozambique 130,000 91,000 17,395 12,200
Namibia 16,000 10,000 9009 8600
Nigeria 360,000 280,000 20,401 17,900
Rwanda 22,000 17,000 7541 4900
South Africa 330,000 300,000 108,682 79,400
Tanzania 160,000 110,000 19,854 18,700
Uganda 150,000 120,000 20,017 19,400
Vietnam Not available Not available 2668 2100
Zambia 120,000 98,000 25,388 21,000
Total 1,640,000∥ 1,252,200¶ 297,440 249,187
*
United Nations Children’s Fund. Children and AIDS: Fifth Stocktaking Report, 2010.
†
Joint United Nations Programme on HIV/AIDS. Global HIV/AIDS Response: Epidemic Update and Health Sector Progress Toward Universal 
Access. Progress report 2011.
‡
Unpublished data, Office of the Global AIDS Coordinator, PEPFAR. Numbers >1000 are rounded to the nearest hundred.
§
United Nations Children’s Fund. Children and AIDS: Fourth Stocktaking Report, 2009. The estimated number of children living with HIV 
reported for Côte d’Ivoire is for 2007. No data are available for 2009.
∥
The total does not include data for Vietnam or Guyana as these numbers were not reported.
¶
The total does not include data for Ethiopia, Vietnam, or Guyana as these numbers were not reported.
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